Premium
Salicylic Acid‐Based Polymeric Contrast Agents for Molecular Magnetic Resonance Imaging of Prostate Cancer
Author(s) -
Banerjee Sangeeta Ray,
Song Xiaolei,
Yang Xing,
Minn Il,
Lisok Ala,
Chen Yanrong,
Bui Albert,
Chatterjee Samit,
Chen Jian,
van Zijl Peter C. M.,
McMahon Michael T.,
Pomper Martin G.
Publication year - 2018
Publication title -
chemistry – a european journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.687
H-Index - 242
eISSN - 1521-3765
pISSN - 0947-6539
DOI - 10.1002/chem.201800882
Subject(s) - magnetic resonance imaging , nuclear magnetic resonance , chemistry , biodistribution , molecular imaging , prostate cancer , in vivo , magnetic resonance spectroscopic imaging , ligand (biochemistry) , salicylic acid , cancer , receptor , in vitro , medicine , biochemistry , radiology , physics , microbiology and biotechnology , biology
Chemical exchange saturation transfer (CEST) magnetic resonance imaging (MRI) is an innovative molecular imaging technique in which contrast agents are labeled by saturating their exchangeable proton spins by radio‐frequency irradiation. Salicylic acid and its analogues are a promising class of highly sensitive, diamagnetic CEST agents. Herein, polymeric agents grafted with salicylic acid moieties and a known high‐affinity ligand targeting prostate‐specific membrane antigen in approximately 10:1 molar ratio were synthesized to provide sufficient MRI sensitivity and receptor specificity. The proton‐exchange properties of the contrast agent in solution and in an experimental murine model are reported to demonstrate the feasibility of receptor‐targeted CEST MRI of prostate cancer. Furthermore, the CEST imaging data were validated with an 111 In‐labeled analogue of the agent by in vivo single photon emission computed tomographic imaging and tissue biodistribution studies.